Sarcoma
Volume 2008 (2008), Article ID 849156, 7 pages
doi:10.1155/2008/849156
Research Article

Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs

Séverine Tabone-Eglinger,1,2 Radislav Bahleda,1 Jean-François Côté,3 Philippe Terrier,4 Dominique Vidaud,5 Anne Cayre,6 Alain Beauchet,7 Nathalie Théou-Anton,1 Marie-José Terrier-Lacombe,4 Antoinette Lemoine,1 Frédérique Penault-Llorca,6 Axel Le Cesne,4 and Jean-François Emile1,7

1INSERM U602, Hôpital Paul Brousse, 12 Avenue P. Vaillant Couturier, 94800 Villejuif, France
2INSERM U590, Centre Léon Bérard, 28 rue Laënnec, 69373 Lyon, Cedex 8, France
3INSERM UMR-S775, Université Paris Descartes, Centre Universitaire des Saints-Pères, 45 r des Saints-Pères, 75006 Paris, France
4Institut Gustave-Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
5INSERM U745, Faculté des Sciences Pharmaceutiques et Biologiques, Université René Descartes, 4 Avenue de L'Observatoire, 75270 Paris, Cedex 6, France
6Anatomie et Cytologie Pathologiques, Centre Jean Perrin, 39 rue Montalembert, 63000 Clermont-Ferrand, France
7Hôpital Ambroise Paré, APHP and Faculté de médecine PIFO, UVSQ - 9, Avenue Charles de Gaulle, 92104 Boulogne, France

Received 22 October 2007; Revised 28 March 2008; Accepted 7 July 2008

Academic Editor: Beatrice Seddon

Copyright © 2008 Séverine Tabone-Eglinger et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. E. Ferner and D. H. Gutmann, “International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis,” Cancer Research, vol. 62, no. 5, pp. 1573–1577, 2002.
  2. L. J. Helman and P. Meltzer, “Mechanisms of sarcoma development,” Nature Reviews Cancer, vol. 3, no. 9, pp. 685–694, 2003. View at Publisher · View at Google Scholar · View at PubMed
  3. J. M. Friedman, “Epidemiology of neurofibromatosis type 1,” American Journal of Medical Genetics Part C, vol. 89, no. 1, pp. 1–6, 1999. View at Publisher · View at Google Scholar
  4. S. M. Huson, P. S. Harper, and D. A. S. Compston, “Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales,” Brain, vol. 111, no. 6, pp. 1355–1381, 1988. View at Publisher · View at Google Scholar
  5. V. M. Riccardi, Neurofibromatosis: Phenotype, Natural History, and Pathogenesis, John Hopkins University Press, Baltimore, Md, USA, 1992.
  6. R. Ballester, D. Marchuk, M. Boguski, et al., “The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins,” Cell, vol. 63, no. 4, pp. 851–859, 1990. View at Publisher · View at Google Scholar
  7. D. H. Gutmann, D. L. Wood, and F. S. Collins, “Identification of the neurofibromatosis type 1 gene product,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 21, pp. 9658–9662, 1991. View at Publisher · View at Google Scholar
  8. M. R. Wallace, D. A. Marchuk, L. B. Andersen, et al., “Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients,” Science, vol. 249, no. 4965, pp. 181–186, 1990. View at Publisher · View at Google Scholar
  9. K. Leroy, V. Dumas, N. Martin-Garcia, et al., “Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: a clinicopathologic and molecular study of 17 patients,” Archives of Dermatology, vol. 137, no. 7, pp. 908–913, 2001.
  10. J. E. DeClue, S. Heffelfinger, G. Benvenuto, et al., “Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models,” The Journal of Clinical Investigation, vol. 105, no. 9, pp. 1233–1241, 2000. View at Publisher · View at Google Scholar · View at PubMed
  11. H. Li, S. Velasco-Miguel, W. C. Vass, L. F. Parada, and J. E. DeClue, “Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model,” Cancer Research, vol. 62, no. 15, pp. 4507–4513, 2002.
  12. B. C. Ling, J. Wu, S. J. Miller, et al., “Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis,” Cancer Cell, vol. 7, no. 1, pp. 65–75, 2005. View at Publisher · View at Google Scholar · View at PubMed
  13. M. S. Stonecypher, S. J. Byer, W. E. Grizzle, and S. L. Carroll, “Activation of the neuregulin-1/ErbB signaling pathway promotes the proliferation of neoplastic Schwann cells in human malignant peripheral nerve sheath tumors,” Oncogene, vol. 24, no. 36, pp. 5589–5605, 2005. View at Publisher · View at Google Scholar · View at PubMed
  14. V. M. N. Riccardi, “Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference,” Archives of Neurology, vol. 45, no. 5, pp. 575–578, 1988.
  15. D. N. Louis, H. Ohgaki, O. D. Wiestler, et al., “The 2007 WHO classification of tumours of the central nervous system,” Acta Neuropathologica, vol. 114, no. 2, pp. 97–109, 2007. View at Publisher · View at Google Scholar · View at PubMed
  16. P. Lévy, D. Vidaud, K. Leroy, et al., “Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR,” Molecular Cancer, vol. 3, article 20, pp. 1–13, 2004. View at Publisher · View at Google Scholar · View at PubMed
  17. M. A. Watson, A. Perry, T. Tihan, et al., “Gene expression profiling reveals unique molecular subtypes of neurofibromatosis type I-associated and sporadic malignant peripheral nerve sheath tumors,” Brain Pathology, vol. 14, no. 3, pp. 297–303, 2004.
  18. S. J. Miller, F. Rangwala, J. Williams, et al., “Large-scale molecular comparison of human Schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues,” Cancer Research, vol. 66, no. 5, pp. 2584–2591, 2006. View at Publisher · View at Google Scholar · View at PubMed
  19. C. H. Chung, K. Ely, L. McGavran, et al., “Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas,” Journal of Clinical Oncology, vol. 24, no. 25, pp. 4170–4176, 2006. View at Publisher · View at Google Scholar · View at PubMed
  20. F. Cappuzzo, G. Finocchiaro, R. Trisolini, et al., “Perspectives on salvage therapy for non-small-cell lung cancer,” Oncology, vol. 19, no. 8, pp. 989–995, 2005.
  21. M. Moroni, S. Veronese, S. Benvenuti, et al., “Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study,” The Lancet Oncology, vol. 6, no. 5, pp. 279–286, 2005. View at Publisher · View at Google Scholar · View at PubMed
  22. A. Perry, S. N. Kunz, C. E. Fuller, et al., “Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms,” Journal of Neuropathology and Experimental Neurology, vol. 61, no. 8, pp. 702–709, 2002.
  23. R. S. Bridge, Jr., J. A. Bridge, J. R. Neff, S. Naumann, P. Althof, and L. A. Bruch, “Recurrent chromosomal imbalances and structurally abnormal breakpoints within complex karyotypes of malignant peripheral nerve sheath tumour and malignant triton tumour: a cytogenetic and molecular cytogenetic study,” Journal of Clinical Pathology, vol. 57, no. 11, pp. 1172–1178, 2004. View at Publisher · View at Google Scholar · View at PubMed
  24. K. Cichowski, T. S. Shih, E. Schmitt, et al., “Mouse models of tumor development in neurofibromatosis type 1,” Science, vol. 286, no. 5447, pp. 2172–2176, 1999. View at Publisher · View at Google Scholar
  25. K. S. Vogel, L. J. Klesse, S. Velasco-Miguel, K. Meyers, E. J. Rushing, and L. F. Parada, “Mouse tumor model for neurofibromatosis type 1,” Science, vol. 286, no. 5447, pp. 2176–2179, 1999. View at Publisher · View at Google Scholar
  26. K. Karube, K. Nabeshima, M. Ishiguro, M. Harada, and H. Iwasaki, “cDNA microarray analysis of cancer associated gene expression profiles in malignant peripheral nerve sheath tumours,” Journal of Clinical Pathology, vol. 59, no. 2, pp. 160–165, 2006. View at Publisher · View at Google Scholar · View at PubMed
  27. B. S. Ducatman, B. W. Scheithauer, D. G. Piepgras, H. M. Reiman, and D. M. Ilstrup, “Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases,” Cancer, vol. 57, no. 10, pp. 2006–2021, 1986. View at Publisher · View at Google Scholar
  28. J. Harding and B. Burtness, “Cetuximab: an epidermal growth factor receptor chimeric human-murine monoclonal antibody,” Drugs of Today, vol. 41, no. 2, pp. 107–127, 2005. View at Publisher · View at Google Scholar · View at PubMed
  29. M. P. Cunningham, S. Essapen, H. Thomas, et al., “Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer,” International Journal of Oncology, vol. 27, no. 2, pp. 317–325, 2005.
  30. R. C. Lilenbaum, “The evolving role of cetuximab in non-small cell lung cancer,” Clinical Cancer Research, vol. 12, no. 14, pp. 4432s–4435s, 2006. View at Publisher · View at Google Scholar · View at PubMed
  31. J. Wu, J. T. Crimmins, K. R. Monk, et al., “Perinatal epidermal growth factor receptor blockade prevents peripheral nerve disruption in a mouse model reminiscent of benign world health organization grade I neurofibroma,” The American Journal of Pathology, vol. 168, no. 5, pp. 1686–1696, 2006. View at Publisher · View at Google Scholar
  32. C. L. Corless, J. A. Fletcher, and M. C. Heinrich, “Biology of gastrointestinal stromal tumors,” Journal of Clinical Oncology, vol. 22, no. 18, pp. 3813–3825, 2004. View at Publisher · View at Google Scholar · View at PubMed
  33. M. Tateishi, T. Ishida, S. Kohdono, M. Hamatake, Y. Fukuyama, and K. Sugimachi, “Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma,” Surgical Oncology, vol. 3, no. 2, pp. 109–113, 1994. View at Publisher · View at Google Scholar